Form 4 for JANX Janux Therapeutics, Inc.
Accepted 2024-09-27 00:00:00 ET · period of report 2024-09-27 · accession 0001415889-24-024076 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2024-09-27 | 2024-09-27 | JANX | DiRaimondo Thomas | CSO | S - Sale | $46.35 | -5,000 | 97.9K | -5% | -$231.7K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-09-27 | S | D | 4,325 | $46.21 | 98,613 | D | — | — | (F2) The weighted average sale price for the transaction reported was $46.2057 and the range of prices were between $45.70 and $46.69. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. (F3) Includes 1,406 shares acquired under the Issuer's 2021 Employee Stock Purchase Plan on May 15, 2024. |
| 2 | Common | Common Stock | 2024-09-27 | S | D | 675 | $47.22 | 97,938 | D | — | — | (F4) The weighted average sale price for the transaction reported was $47.2245 and the range of prices were between $46.79 and $47.77. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. |